Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Starting treatment on the day of HIV diagnosis is acceptable and feasible for Thai patients

Starting treatment on the day of HIV diagnosis is acceptable and feasible for Thai patients, and people who started treatment very soon after diagnosis were more than

Published
17 August 2018
By
Keith Alcorn
New HIV therapy reduces virus, boosts immunity in drug-resistant patients

Ibaluzimab, a CD4 receptor inhibitor and the first monoclonal antibody developed as an anti-HIV drug, was approved for treatment in the US for people with multiply drug-resistant HIV (MDR-HIV) last February. In the results of a phase III study published today, 83% of a group of patients with MDR-HIV achieved an undetectable viral load on ibaluzimab and 50% maintained this over six months. Details of this and another phase III study will be presented later htis year.

Published
16 August 2018
From
Science Daily
Should Gilead Be Worried About This New Monthly HIV Medication?

Yesterday, Johnson & Johnson and ViiV Healthcare announced positive results from the Atlas phase 3 study testing their two-drug HIV treatment containing an investigational drug cabotegravir and rilpivirine, a nucleoside reverse transcriptase inhibitor (NRTI) sold by Johnson & Johnson as Edurant. The important thing here isn't going from three medications to two, but that ViiV and Johnson & Johnson's cabotegravir and rilpivirine combination is injected once a month compared to a daily therapy for the three-drug combination.

Published
16 August 2018
From
Motley Fool
HIV drug research in Wales to cut infection risk

Nearly 400 people have been taking part in a three-year trial of the drugs in Wales since last summer. Cardiff University will now examine how people have been taking the medicine - and if that affects the protection.

Published
16 August 2018
From
BBC
One in nine people may be able to control their viral load after stopping treatment, US study finds

A US collaboration that pooled data from 14 scientific studies containing between them more than 600 HIV-positive people has found that 67 of them were able to

Published
16 August 2018
By
Gus Cairns
ViiV, Janssen’s two-drug HIV regimen hits PhIII targets

ViiV Healthcare and Janssen have unveiled positive headline data from a late-stage trial of their injectable two-drug regimen for the treatment of HIV.

Published
15 August 2018
From
Pharma Times
Lynne Mofenson, M.D., Explains the Dolutegravir Risks for People With HIV Who Want to Get Pregnant

Lynn Mofenson, M.D., who is a researcher with the Elizabeth Glaser Pediatric AIDS Foundation, explains what is known about the potential risk of neural tube defects when dolutegravir is used around the time of conception.

Published
15 August 2018
From
The Body PRO
Studies show dolutegravir monotherapy is an unsafe switch option

Using dolutegravir alone, as maintenance treatment after achieving undetectable viral load on a three-drug regimen, results in an unacceptable rate of viral rebound and is unethical in

Published
09 August 2018
By
Keith Alcorn
Diarrhoea continues to affect the quality of life of people with HIV in the modern treatment era

A meta-analysis of 38 clinical trials of antiretroviral therapies (ART) conducted in the past decade found that an average of 17% of study participants suffered from diarrhoea,

Published
07 August 2018
By
Roger Pebody
How Will Long-Acting HIV Antiretrovirals Work in the Real World?

While there has been considerable buzz within the HIV workforce about the promise of long-acting antiretrovirals to transform both HIV prevention and treatment, a critical question hangs in the air: Once viable long-acting options have reached the market, what will be their true impact? Will they really help move us toward an HIV-free world?

Published
01 August 2018
From
The Body Pro
← First12345...477Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.